Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE8B | O95263 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863645 | 0.91 | PPARA (0.55) | PPARAPPARGTP53LMNAALDH1A1 | |
| SCHEMBL1866982 | 0.89 | PPARA (0.60) | PPARAPPARGKDM4ERAB9AMEN1 | |
| SCHEMBL1866727 | 0.88 | PPARA (0.50) | PPARAPPARGPDE8B | |
| SCHEMBL12802466 | 0.87 | PPARA (0.56) | PPARAPPARGPDE8B | |
| SCHEMBL1863946 | 0.86 | PPARA (0.62) | PPARAPPARGTP53LMNAMEN1 | |
| SCHEMBL12803009 | 0.83 | PPARA (0.56) | PPARAPPARGKDM4ERAB9AMEN1 | |
| SCHEMBL1867205 | 0.83 | PPARA (0.47) | PPARAPPARGPDE8B | |
| SCHEMBL1868386 | 0.82 | PPARA (0.57) | PPARAPPARGTP53LMNAALDH1A1 | |
| SCHEMBL1867415 | 0.82 | PPARA (0.56) | PPARAPPARGLMNAALDH1A1KDM4E | |
| SCHEMBL1869557 | 0.82 | PPARA (0.54) | PPARAPPARGKDM4ERAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | claimed |
| EP-2694513-B1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-01-07 | — | — | EP | claimed |
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | claimed |
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| EP-2694513-B1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| US-8748435-B2 | Pyrazolo pyrimidine derivatives | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | disclosed |
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | THPO, P2RX3, P2RX5 | PPARA 287/4885PPARG 183/4885TP53 823/4885 |
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | GPR4, FABP6, GIPR | PPARA 686/4885PPARG 316/4885TP53 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.